NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/24/2026 15:18
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization124.09 mln
Float17.54 mln
Earnings Date08/18/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
15.21
Transformational upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-58.37
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Coya Therapeutics is a Houston-based clinical-stage biotech company founded in 2020 that focuses on treatments designed to boost the body's regulatory immune cells, known as Tregs, to fight neurological and inflammatory diseases such as ALS, Alzheimer's, Parkinson's, and frontotemporal dementia. Its most advanced drug candidate, COYA 302, is currently in Phase 2 trials and is being developed in partnership with Dr. Reddy's Laboratories. The company also has several earlier-stage candidates targeting autoimmune, neurodegenerative, and metabolic conditions through a range of biological approaches.
